Related by context. All words. (Click for frequent words.) 73 hematologic 68 haematological 64 haematologic 61 hematological diseases 61 hematologic cancers 60 cytogenetic responses 60 essential thrombocythemia 60 complete remissions 59 hematological malignancies 58 myelofibrosis polycythemia vera 58 NAGS deficiency 58 indolent NHL 57 myeloproliferative neoplasms 57 carcinoid 57 partial remissions 57 histologic subtype 57 hematologic malignancies 57 sarcomatoid 57 myeloproliferative diseases 57 CHOP chemotherapy 57 neoplastic 57 kidney urologic 57 follicular lymphoma FL 57 histologies 57 follicular NHL 57 metastatic GIST 57 galiximab 57 neutropenia dehydration dyspnea 57 cytopenias 57 tumor malignancies 57 severe hypersensitivity reactions 57 tumoral 57 pheochromocytoma 57 pomalidomide 56 Myelofibrosis 56 platinum refractory 56 imatinib resistant 56 pancytopenia 56 epithelial tumors 56 papillary renal cell carcinoma 56 MabThera Rituxan 56 neuroendocrine cancers 56 aHUS 56 TTF Therapy 56 Amrubicin 56 haematological malignancies 56 pediatric acute lymphoblastic 56 xenograft models 56 gemcitabine Gemzar ® 56 thalidomide Thalomid 56 relapsed MM 56 cutaneous T 56 mycosis fungoides 56 ara C 56 leukemia CML 55 multiple myeloma MM 55 CVP chemotherapy 55 acute GvHD 55 cytogenetic response 55 relapsed refractory multiple myeloma 55 metastatic CRC 55 atypical Hemolytic Uremic Syndrome 55 myelosuppression 55 relapsed refractory 55 Diffuse Large B 55 dasatinib Sprycel ® 55 receptor tyrosine kinase inhibitor 55 heavily pretreated 55 MCyR 55 heavily pretreated patients 55 CRp 55 chronic lymphocytic leukemia CLL 55 esophageal candidiasis 55 chronic myeloid leukemia CML 55 Hematologic 55 systemic anaplastic large 55 myelodysplastic syndrome MDS 55 Cloretazine 55 vinca alkaloid 55 histone deacetylase HDAC inhibitor 55 lenalidomide Revlimid R 55 lupus nephritis 55 Myelodysplastic syndromes MDS 55 hematologic toxicity 55 hematologic disorders 55 hA# 55 SJIA 55 grade cervical intraepithelial 55 erlotinib Tarceva ® 55 pan HDAC inhibitor 55 peripheral blood mononuclear 55 Fludara 55 splenectomized patients 54 FavId 54 erythropoietic 54 CYT# potent vascular disrupting 54 taxane refractory 54 unfavorable cytogenetics 54 oral prodrug 54 Omacetaxine 54 leukemia ALL 54 FluCAM arm 54 hypereosinophilic syndrome 54 chemotherapy regimens 54 metastatic malignant 54 HSCT 54 ELACYT 54 GISTs 54 Chronic lymphocytic leukemia CLL 54 imatinib Gleevec 54 Ribavirin causes 54 myelofibrosis 54 elacytarabine 54 tumor lysis syndrome 54 Gleevec resistant 54 cell lymphomas 54 metastatic lesions 54 gastrointestinal stromal tumor GIST 54 cell lymphoma CTCL 54 Sudhir Agrawal D.Phil 54 fibrotic disease 54 neurological manifestations 54 leukemia AML 54 calcineurin inhibitors 54 tumors GIST 54 glioblastoma multiforme GBM 54 deletion 5q 54 refractory chronic lymphocytic 54 Lymphomas 54 lymphoma subtypes 54 malignancies 54 Chronic lymphocytic leukemia 54 pegylated interferon alpha 54 antimetabolite 54 Xanafide 54 assessing T DM1 54 acute leukemias 54 Darinaparsin 54 caspofungin 54 refractory AML 54 Ph + ALL 54 GvHD 54 docetaxel chemotherapy 54 KRAS wild 54 tumor xenograft models 54 squamous 54 lymphocytosis 54 essential thrombocythemia ET 54 myeloproliferative 54 alkylating agent 54 myeloproliferative disorders 54 Alocrest 54 carcinoids 54 HER2 positive metastatic breast 54 histological subtype 54 serous ovarian cancer 54 hematological cancers 53 TELINTRA 53 non Hodgkin lymphomas 53 Fludara ® 53 Azedra 53 mucinous 53 refractory cutaneous T 53 Toxicities 53 cisplatin gemcitabine 53 panobinostat 53 febrile neutropenia 53 lymphoma leukemia 53 hemolytic anemia 53 refractory NSCLC 53 haematological cancers 53 Chronic Lymphocytic Leukemia CLL 53 unknown etiology 53 resistant ovarian cancer 53 superficial bladder cancer 53 histologic 53 Vidofludimus 53 lenalidomide dexamethasone 53 gastrointestinal stromal tumors GIST 53 allogeneic bone marrow 53 EGFR HER2 53 chronic GVHD 53 CLL SLL 53 PNH patients 53 purpura ITP 53 anti angiogenic agents 53 CD# mAb 53 relapsed multiple myeloma 53 PNP inhibitor 53 astrocytoma 53 Doxil ® 53 azacitidine 53 familial amyloidotic polyneuropathy FAP 53 dasatinib Sprycel 53 alvespimycin 53 common hematologic malignancy 53 acute coronary syndromes ACS 53 neoplasm 53 atypical hemolytic uremic syndrome 53 mTOR inhibitors 53 myelodysplastic syndromes MDS 53 hepatorenal syndrome 53 gemcitabine carboplatin 53 peripheral sensory neuropathy 53 amrubicin 53 metastatic renal cell 53 azacytidine 53 BCG refractory 53 gastroduodenal 53 malignant lymphomas 53 LHRH receptor positive 53 mRCC 53 immunomodulatory therapy 53 relapsed mantle 53 hematopoietic cell 53 idiopathic thrombocytopenic purpura 53 pain palliation 53 metastatic neuroendocrine tumors 53 myelodysplastic myeloproliferative diseases 53 leukaemias 53 CVP cyclophosphamide vincristine 53 cutaneous T cell 53 TREANDA 53 thymoma 53 demonstrated antitumor activity 53 intravenous immunoglobulin 53 cancer mCRC 53 crizotinib PF # 53 histological subtypes 53 systemic lupus erythematosus SLE 53 kinase inhibition 53 gastric carcinoma 53 obatoclax 53 anemia neutropenia 53 hematological disorders 53 daunorubicin 53 idiopathic thrombocytopenic purpura ITP 53 carcinoid tumors 52 receiving highly emetogenic 52 nucleoside analogues 52 sJIA 52 Acute lymphoblastic leukemia 52 thyroid carcinoma 52 SCCHN 52 hypercalcemia 52 advanced metastatic renal 52 CA4P 52 leukemias lymphomas 52 biologic therapy 52 Pharmacokinetics PK 52 cetuximab Erbitux ® 52 hepatic encephalopathy HE 52 PI3K/Akt pathway inhibitor 52 Follicular Lymphoma 52 PDX pralatrexate 52 gastrointestinal stromal tumors GISTs 52 MGd 52 recombinant enzyme 52 tanespimycin 52 systemic ALCL 52 standard chemotherapy regimens 52 polycythemia vera essential thrombocythemia 52 micafungin 52 HBeAg positive patients 52 Fludarabine 52 bendamustine 52 cell lymphoma ALCL 52 severe malignant osteopetrosis 52 Bezielle 52 Panzem R NCD 52 TNF antagonist 52 FluCAM 52 prokinetic agent 52 leukemic 52 BCR ABL mutations 52 AEG# 52 Specifid 52 imatinib Gleevec ® 52 sorafenib Nexavar 52 Pathway Inhibitor 52 genitourinary GU 52 infusion reactions 52 eculizumab 52 AGHD 52 neuroendocrine tumors 52 Aflibercept 52 relapsed refractory aggressive 52 lymphoid malignancies 52 complement inhibitor eculizumab 52 C1 INH 52 endometrioid 52 proctitis 52 JAK inhibitors 52 chlorambucil 52 anti leukemic 52 polycythemia vera PV 52 CR CRu 52 allogeneic stem cell 52 follicular lymphomas 52 hepatocellular carcinoma HCC 52 DOXIL 52 KRAS mutations occur 52 previously untreated follicular 52 imatinib therapy 52 Telintra 52 recurrent glioblastoma multiforme 52 immune modulating 52 adriamycin 52 refractory chronic myeloid 52 etoposide 52 pharmacodynamic PD 52 OHR/AVR# 52 Certolizumab pegol 52 breast carcinoma 52 neutropaenia 52 Non Hodgkin lymphoma 52 leukemia CLL 52 FLT3 52 transplantation HCT 52 hypoxia inducible factor 52 hematopoietic cancers 52 hepatic cirrhosis 52 Leukemias 52 taxane chemotherapy 52 Vidaza ® 52 LHRH analogues 52 HGS ETR1 52 preclinical xenograft models 52 Flu Cy 52 chronic eosinophilic leukemia 52 veltuzumab 52 astrocytomas 52 gastrointestinal toxicities 52 TRAIL R1 52 erythema nodosum 52 pancreatic adenocarcinoma 52 extracranial 52 Evoltra ® 52 novel histone deacetylase 52 depsipeptide 52 lymphomas 52 HeFH 52 adverse cytogenetics 52 EGFR tyrosine kinase inhibitors 52 OncoVEX GM CSF 52 chemotherapeutic regimens 52 graft dysfunction 52 hypomethylating agents 52 tumor necrosis 52 steroid refractory GvHD 52 posaconazole 52 acute myeloid 52 EGFR targeting 52 osteosarcomas 52 acute myeloid leukemia AML 51 tyrosine kinase inhibitors TKIs 51 HGS ETR2 51 pamidronate 51 RezularTM 51 mCRC patients 51 T#I mutation 51 myeloablative 51 Kepivance 51 HGS# 51 investigational therapies 51 Glucocorticoids 51 Zavesca R 51 immune thrombocytopenic purpura ITP 51 Annamycin 51 systemic lupus erythematosus 51 lymphoid tumors 51 neurogenic 51 Sezary syndrome 51 epirubicin 51 Tarceva erlotinib 51 CANCIDAS 51 gastrointestinal perforation 51 paroxysmal nocturnal hemoglobinuria PNH 51 Kit CD# positive 51 enzastaurin 51 hemorrhagic cystitis 51 GRN#L 51 MELAS 51 Acute Myeloid Leukemia AML 51 breast cancer subtypes 51 SinuNase TM 51 cilengitide 51 huN# DM1 51 Cloretazine R VNP#M 51 hypophosphatasia 51 haematopoietic 51 lomitapide 51 basal cell carcinoma BCC 51 malignant gliomas 51 lymphoid 51 certolizumab 51 AQ4N 51 leucopenia 51 leukemia APL 51 rituximab 51 refractory acute myeloid 51 proteasome inhibitor 51 NMIBC 51 hematopoietic stem cell 51 pegylated liposomal doxorubicin 51 papillary 51 Enzastaurin 51 Epratuzumab 51 antibody MAb 51 interferon alfa 2b 51 immune modulator 51 Dacogen injection 51 Elagolix 51 MEK inhibitors 51 skeletal metastases 51 Acute myeloid leukemia 51 Vorinostat 51 Raptiva ® 51 anticancer treatments 51 tigecycline 51 cyclophosphamide doxorubicin vincristine 51 lymphoproliferative disorders 51 demyelinating diseases 51 vinorelbine 51 cisplatin chemotherapy 51 Hurthle cell 51 pulmonary metastases 51 Personalized Immunotherapy 51 Follicular lymphoma 51 Hodgkin lymphoma NHL 51 metastatic renal cell carcinoma 51 MYLOTARG 51 hematologic malignancy 51 riociguat 51 dexamethasone Decadron 51 standard chemotherapy regimen 51 bladder carcinoma 51 smoldering myeloma 51 mycophenolate mofetil 51 malignant neoplasms 51 non metastatic osteosarcoma 51 milatuzumab 51 docetaxel Taxotere ® 51 soft tissue sarcomas 51 ponatinib 51 myeloid 51 ovarian carcinoma 51 DMARD 51 metastatic HRPC 51 taxane resistant 51 eosinophilic asthma 51 grade cervical dysplasia 51 mitomycin 51 lumiliximab 51 immune thrombocytopenic purpura 51 taxanes 51 MALT lymphoma 51 pericardial effusion 51 EGFR mutation positive 51 EGFR expressing mCRC 51 cytokine refractory 51 breast carcinomas 51 allogeneic HSCT 51 primary hyperparathyroidism 51 nucleoside analogs 51 small lymphocytic lymphoma 51 relapsing remitting 51 molecular remissions 51 DMARDS 51 unresectable 51 MDS AML 51 Gleevec imatinib mesylate 51 YONDELIS 51 ceftazidime 51 adrenocortical carcinoma 51 Allovectin 7 ® 51 alkylating agents 51 dosing cohort 51 radiotherapeutic 51 neoplasms 51 myelodysplastic syndromes 51 evaluating REVLIMID 51 acute promyelocytic leukemia APL 50 fungoides 50 liposomal formulation 50 Natalizumab 50 antigen CD# 50 antiemetics 50 Cutaneous T 50 FOLFOX chemotherapy 50 monoclonal gammopathy 50 esophageal carcinoma 50 pertuzumab 50 Soft Tissue Sarcoma 50 idiopathic myelofibrosis 50 sorafenib Nexavar ® 50 Neulasta ® 50 hydroxymethyl coenzyme 50 chemo resistant 50 hepatocellular carcinomas 50 PEGylated Fab fragment 50 Letairis ambrisentan 50 ofatumumab 50 Ph + acute lymphoblastic 50 differentiated thyroid 50 Anaplastic 50 mitoxantrone 50 Phase #b/#a clinical 50 nilotinib Tasigna ® 50 velafermin 50 sarcomas 50 lung cancer NSCLC 50 bortezomib Velcade R 50 follicular lymphoma 50 TheraSphere 50 refractory CTCL 50 immune dysregulation 50 cytoreduction 50 splenectomized 50 registrational trial 50 cetuximab Erbitux R 50 bevacizumab Avastin ® 50 IV NSCLC 50 imatinib mesylate 50 IL 1ß 50 EGFR expressing 50 malignant pheochromocytoma 50 anthracyclines taxanes 50 decitabine 50 VNP#M 50 bortezomib Velcade 50 Glioblastoma multiforme GBM 50 axitinib 50 PXD# 50 coagulation disorders 50 TNF blocker therapy 50 mycophenolate mofetil MMF 50 generalized seizures 50 elotuzumab 50 gastrointestinal stromal tumor 50 HuMax CD4 50 Pegasys ® 50 BR.# 50 chronic myelogenous leukemia CML 50 pimecrolimus cream 50 forodesine 50 Phase #/#a trial 50 diabetic nephropathy 50 squamous cell lung cancer 50 REVLIMID R 50 ZEVALIN 50 Solid Tumors 50 trabectedin 50 non splenectomized 50 monoclonal antibody conjugated 50 Zenvia ™ 50 metastatic liver 50 temsirolimus Torisel ® 50 visceral metastases 50 intra abdominal abscess 50 potentially hepatotoxic 50 Renal Cell Carcinoma RCC 50 biliary tract cancer 50 docetaxel Taxotere R 50 chemotherapeutic regimen 50 Azacitidine 50 Neutropenia 50 thromboembolic 50 ixabepilone 50 gemcitabine Gemzar 50 RoACTEMRA 50 solid tumors 50 nilotinib 50 TTR gene 50 disease modifying antirheumatic 50 locoregional recurrence 50 sunitinib malate 50 rituximab refractory 50 squamous cell carcinoma SCC 50 immunocompetent 50 BCR ABL mutation 50 VIDAZA 50 oblimersen 50 metastatic melanoma 50 HER2 overexpression 50 chronic granulomatous disease 50 SPRYCEL ® 50 evaluating tivozanib 50 hematopoietic malignancies 50 AA Amyloidosis 50 pegfilgrastim 50 thymic carcinoma 50 porcine derived 50 Carcinoid tumors 50 lymphocytic leukemia 50 situ CIS 50 pancreatic carcinoma 50 rituximab Rituxan 50 IMGN# 50 sunitinib 50 CTEPH 50 rFVIIa 50 hyperphenylalaninemia HPA due 50 tumor histology 50 microtubule inhibitor 50 radiochemotherapy 50 PEGylated anti 50 GEMZAR 50 2 methoxyestradiol 50 advanced carcinoid 50 ansamycin 50 Squalamine 50 dacarbazine 50 EGFR inhibitors 50 visilizumab 50 paragangliomas 50 antithymocyte globulin 50 dextromethorphan quinidine 50 cholangiocarcinoma 50 recombinant erythropoietin 50 ribavirin therapy 50 thetreatment 50 JMML 50 malignant neoplasm 50 lymphocytic 50 sodium stibogluconate 50 dose cohorts 50 Vidaza R 50 evaluable 50 Gel repository corticotropin injection 50 Apoptone 50 Sjögren syndrome 50 macrovascular events 50 Acute Myelogenous Leukemia AML 50 EOquin TM 50 prostate carcinoma 50 DMARDs 50 candidemia 50 recurrent glioblastoma 50 tyrosine kinase inhibitors 50 Phase 2a trial 50 TEAEs 50 proliferative diabetic retinopathy 50 liposomal amphotericin B 50 VAPRISOL 50 chronic myeloid 50 taxane therapy 50 cytarabine 50 adrenocortical cancer 50 Hurler syndrome 50 epratuzumab 50 calcineurin inhibitor 50 papillary carcinoma 50 invasive candidiasis 50 delayed CINV 50 Candida infection 49 TNF Tumor Necrosis Factor 49 superficial basal cell carcinoma 49 immunological diseases 49 histone deacetylase inhibitor 49 nosocomial pneumonia 49 carcinoma HCC 49 pegylated interferon alfa 49 idarubicin 49 Folfox 49 monoclonal antibody therapies 49 surrogate endpoint 49 HRPC 49 irinotecan containing 49 juvenile myelomonocytic leukemia 49 Tarceva TM 49 cytotoxic chemotherapy 49 Dasatinib 49 Chronic Myeloid Leukemia CML 49 4mg/kg 49 metastatic colorectal cancer 49 gastrointestinal stromal tumors 49 anthracycline taxane 49 ibritumomab tiuxetan 49 Rituximab 49 Rheumatoid Arthritis RA 49 pancreatic NET 49 lung carcinomas 49 haematologic malignancies 49 olmesartan 49 SSc patients 49 acute lymphoblastic 49 investigational monoclonal antibody 49 metastatic kidney 49 pancreatic islet cell 49 renal cell carcinomas 49 colorectal carcinoma 49 pleomorphic 49 TRISENOX 49 Wegener granulomatosis 49 MGUS 49 pCR 49 epithelioid 49 IMC A# 49 Genasense ® 49 metaglidasen 49 benign prostatic hypertrophy BPH 49 tyrosine kinase inhibitor TKI 49 infantile spasms 49 T1DM 49 Surgical resection 49 uric acid lowering 49 refractory colorectal cancer 49 FUSILEV enhances 49 Alzhemed TM 49 hyperplasia 49 IRX 2 49 efalizumab 49 pulmonary hypertension PH 49 immunosuppressives 49 relapsed leukemia 49 phase Ib 49 malignant pancreatic 49 urothelial 49 cytotoxic agents 49 doxorubicin cyclophosphamide 49 TACE 49 congenital anomalies 49 KRAS status 49 lymphoma CTCL 49 malignant transformation 49 relapsed indolent NHL 49 CIMZIA ™ 49 ribavirin RBV 49 localized renal 49 alefacept 49 LHRH agonists 49 folinic acid 49 liposomal doxorubicin 49 myeloproliferative disorder 49 Seliciclib 49 Elacytarabine 49 rilonacept 49 metastatic sarcoma 49 gastric adenocarcinoma 49 relapsed SCLC 49 Interferon beta 49 INVANZ 49 GIST tumors 49 Sutent sunitinib 49 IL# PE#QQR 49 melphalan prednisone 49 histologically 49 adenomatous 49 immunocompetent patients 49 Hycamtin ® 49 ER CHOP 49 TTR amyloidosis 49 HSP# inhibitor 49 Benlysta belimumab 49 xenograft tumors 49 ependymoma 49 Cell Lymphoma 49 TACI Ig 49 Ozarelix 49 paraganglioma 49 Hodgkin lymphoma HL 49 severe oral mucositis 49 FOLFIRI alone 49 romiplostim 49 PI3K inhibitors 49 metastatic uveal melanoma 49 Lenalidomide 49 pituitary adenomas 49 pancreatic prostate 49 colorectal liver metastases 49 estramustine 49 colorectal lung 49 Taxotere R 49 cell acute lymphoblastic 49 patients evaluable 49 complete cytogenetic 49 hepatocellular carcinoma 49 cell carcinoma 49 huC# DM4 49 tiuxetan 49 MabCampath 49 EFAPROXYN 49 nonalcoholic steatohepatitis NASH 49 nucleotide analog 49 refractory indolent non 49 metastatic malignant melanoma 49 Cloretazine ® 49 carcinomas 49 refractory multiple myeloma 49 Proxinium TM 49 mutated KRAS 49 alfa 2a 49 chronic immune thrombocytopenic 49 mCRC 49 myeloid metaplasia 49 Advanced Renal Cell 49 5 FU leucovorin 49 HP Acthar Gel repository 49 trastuzumab Herceptin R 49 cutaneous squamous cell carcinoma 49 DLBCL 49 recurrent NSCLC 49 ISTODAX 49 Philadelphia Chromosome Positive 49 papillary thyroid carcinoma 49 K ras mutations 49 AA amyloidosis 49 alpha interferons 49 Novantrone 49 Akt inhibitor 49 completely resected 49 endometrial adenocarcinoma 49 BEXXAR 49 recurrent malignant glioma 49 Alessandro Riva 49 glufosfamide 49 invasive bladder 49 Paraplatin ® carboplatin 49 LEUKINE 49 lesional 49 cisplatin resistant 49 subependymal giant cell 49 lymphoid blast 49 benign neoplasms 49 paclitaxel Taxol ® 49 cervical intraepithelial neoplasia 49 Multiple Myeloma MM 49 idiopathic pulmonary fibrosis IPF 49 quinolone 49 NSCLC 49 pleurodesis 49 herpetic keratitis 49 plasma pharmacokinetics 49 Hepatocellular Carcinoma HCC 49 Li Fraumeni Syndrome 49 Etoposide 49 Anthracycline 49 docetaxel Taxotere 49 ritonavir boosted 49 anticancer therapy 49 lymphoproliferative disorder 49 voriconazole 49 invasive aspergillosis 49 basal cell nevus syndrome 49 5-fluorouracil/leucovorin 49 basiliximab 49 refractory metastatic colorectal cancer 49 Velcade bortezomib 49 Voreloxin 49 lymphoma Hodgkin lymphoma 49 relapsed acute lymphoblastic 49 hormone refractory prostate cancer 49 nonmyeloablative 49 trastuzumab Herceptin ® 49 IBS C 49 recurrent GBM 49 cervical carcinoma 49 acyclovir Lauriad R 49 AML acute myeloid 49 invasive ductal 49 deferiprone 49 vasculitis 49 myelomas 49 iniparib 49 macroglobulinemia 49 rituximab refractory follicular 49 Decitabine 49 Carboplatin 49 mapatumumab 49 sunitinib Sutent 49 prednisolone chemotherapy 49 relapsed ovarian cancer 48 prostate cancer PCa 48 refractory Hodgkin lymphoma 48 Taxotere ® 48 leukoencephalopathy 48 renal tumors 48 systemic mastocytosis 48 Navelbine ® 48 malignant ascites 48 gynecological malignancies 48 AP# [003] 48 ependymomas 48 inhaled liposomal ciprofloxacin 48 malignant pleural mesothelioma 48 toxicities 48 sorafenib Nexavar R 48 Atypical Hemolytic Uremic Syndrome 48 FOLFOX4 48 HBeAg negative patients 48 Treanda 48 metastatic renal 48 generalized tonic clonic seizures 48 intravesical therapy 48 CINTREDEKIN BESUDOTOX 48 Orally administered 48 neovascular 48 Relapsed Refractory 48 5 fluorouracil leucovorin 48 Pemetrexed 48 zalutumumab 48 thromboembolic events 48 TORISEL 48 tuberous sclerosis complex 48 MAGE A3 ASCI 48 bexarotene 48 refractory ovarian cancer 48 malignant fibrous histiocytoma 48 Pegylated Interferon 48 Medullary thyroid cancer 48 rituximab monotherapy 48 CsA 48 juvenile idiopathic arthritis 48 lymphoid cells 48 pegylated interferons 48 Glioblastoma Multiforme 48 thrombophilia 48 Multiple myeloma 48 topotecan 48 advanced hepatocellular carcinoma 48 chronic HBV infection 48 Vicinium TM 48 relapsed AML 48 castrate resistant prostate cancer 48 lymphadenopathy 48 oritavancin 48 anthracyclines 48 liver metastasis 48 systemic antifungal 48 taxane 48 corticosteroid therapy 48 PhG alpha 1 48 FOLFOX6 48 metastatic lung cancer 48 pegylated alpha interferon 48 mg/m2 dose 48 pleural effusions 48 Peginterferon alfa 2b 48 overactive bladder syndrome 48 refractory 48 mixed hyperlipidemia 48 Genentech Rituxan 48 therapeutic regimens 48 Platinol ® 48 FOLFIRI 48 medullary thyroid cancer 48 HER2 + 48 PCNSL 48 prednisone prednisolone 48 corticosteroids immunoglobulins 48 Platinol ® cisplatin 48 chemotherapy cisplatin 48 leiomyomas 48 interferon ribavirin 48 Tasimelteon 48 microsphere therapy 48 metastatic colorectal 48 carcinoid tumor 48 ® lenalidomide 48 Phase III randomized controlled 48 plus ribavirin 48 prostate carcinomas 48 hyperoxaluria 48 Helicobacter pylori eradication 48 lupus erythematosus 48 chemoradiotherapy 48 recurrent genital herpes 48 paclitaxel Taxol R 48 operable breast cancer 48 thromboembolic disease 48 Navelbine 48 relapsed acute myelogenous 48 follicular non 48 glioblastoma 48 Alequel 48 non constipating irritable 48 Ph + 48 doxorubicin Adriamycin 48 DMARD therapy 48 histologic subtypes 48 posterior uveitis 48 urothelial carcinoma 48 Saforis 48 temsirolimus Torisel 48 cyclophosphamide methotrexate 48 chemotherapeutic agent 48 pleural fluid 48 Leukine ® 48 Luteinizing Hormone Releasing Hormone 48 renal cell carcinoma 48 neurofibromas 48 Gemzar ® 48 Trastuzumab 48 colony stimulating factors 48 myelosuppressive 48 systemic fungal infections 48 Aurora kinase 48 juvenile idiopathic arthritis JIA